Atypical hearing loss in women with breast cancer receiving adjuvant treatment.
There are no reports of adjuvant treatments for early breast cancer causing hearing loss. Yet in this exploratory study 14/16 women who had received Fluorouracil, Epirubicin and Cyclophosphamide (FEC) chemotherapy regimen, 11 of whom also received endocrine treatment, had reduced hearing sensitivity, with 9/16 being atypical. It is not clear whether this finding is related to oestrogen reduction and/or ototoxicity but a more detailed investigation in this area is warranted given the large number of women with breast cancer who receive adjuvant treatments.
Jenkins
V
V
Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Falmer, East Sussex, and Department of Audiology, Royal Sussex County Hospital, Brighton, UK. val@sussex.ac.uk
Beveridge
H
H
Low
R
R
Mitra
S
S
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001301:Audiometry, Pure-Tone; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects